From: David Chitaia
To: Natia Khmaladze
Date: Wed, 26 Apr 2017 16:55:26 +0400
Subject: Fwd: Belarus letter
From: Graeme Robertson <Graeme.Robertson@gilead.com >
Date: 26 April 2017 at 16:01
Subject: RE: Belarus letter
To: David Chitaia < dchitaia@moh.gov.ge>
Dear David,
It is clause 5 that we are most concerned and Christina in legal will not accept the language you proposed. As we are not party in the agreement between Georgia and Belarus and we are not party to the donations whilst Georgia are the recipients and holder of the drug.
Please can you see if the letter attached as was originally proposed by Gilead is agreeable for Georgia to sign.
Thank you and best wishes
Graeme
Graeme.A Robertson
Senior Director, Africa & CIS
Access Operations & Emerging Markets
------------------------------
Gilead Sciences Europe Ltd • Registered as a limited company in England and Wales • Registered number 05510315
Registered office: South Building • 2 Roundwood Avenue • Stockley Park • Uxbridge • UB11 1AZ • England
Telephone: +44 (0)208 587 2228 • Mobile: +44(0)7789 268 043 • Fax: +44(0)208 744 6773
From: David Chitaia [mailto:dchitaia@moh.gov.ge]
Sent: 24 April 2017 11:18
To: Graeme Robertson
Subject: Re: Belarus letter
Hello Graeme,
Hope everything went well in Amsterdam.
As there were changes to the draft letter, attached please find our comments on them.
Thank you in advance,
Regards,
David.
On 21 April 2017 at 21:23, Graeme Robertson < Graeme.Robertson@gilead.com> wrote:
Dear David
Please find attached our latest draft
Please let me know if this is ok
Thank you
Graeme
Sent from my iPhone
Begin forwarded message:
DISCLAIMER If you have received this message in error, please contact the
sender immediately by return e-mail and notify the sender and then delete
this message (including any attachments) from your system. This
communication and any attachments contain information
which is confidential and may also be legally privileged. It is for the
exclusive use of the intended recipient(s). If you are not the intended
recipient(s) please note that any form of disclosure, distribution, copying
or use of this communication or the
information in it or in any attachments is strictly prohibited and may be
unlawful. E-mail communications cannot be guaranteed to be secure or error
free, as information could be intercepted, corrupted, amended, lost,
destroyed, arrive late or incomplete,
or contain viruses. Gilead does not accept liability for any such matters
or their consequences. Anyone who communicates with Gilead by e-mail is
taken to accept the risks in doing so. Gilead has taken every reasonable
precaution to ensure that any attachment
to this e-mail has been swept for viruses. However, Gilead cannot accept
liability for any damage sustained as a result of viruses and would advise
that you carry out your own virus checks before opening any attachment.
Gilead Sciences Europe Ltd ; Registered
as a limited company in England and Wales ; Registered number 5510315
Registered office: South Building ; 2 Roundwood Avenue ; Stockley Park ;
Uxbridge ; UB11 1AF ; England